Recently, Merit Medical announced that the company has agreed to acquire Cook Medical's guidewire management business for $210 million (approximately RMB 1.5 billion).

Merit expects to fund the transaction through a combination of cash on hand and borrowings under its long-term credit facility. The proposed transaction is expected to close in the fourth quarter of 2024, subject to the receipt or waiver (as specified in the Asset Purchase Agreement) of certain closing conditions, including approvals under antitrust laws and other customary closing conditions.

It is understood that Cook Medical’s lead management business has 34 years of operational history, providing a comprehensive end-to-end portfolio of medical devices and accessories for lead management procedures in patients requiring the removal or replacement of pacemaker or implantable cardioverter-defibrillator (ICD) leads.

Cook Medical’s lead management business provides medical devices and accessories for lead extraction procedures. These procedures are performed in patients who require the removal or replacement of pacemaker or implantable cardioverter-defibrillator (ICD) leads.

Merit Medical stated that Cook Medical generated approximately $37 million in revenue during the 12-month period ended December 31, 2023. The company expects to contribute $4 million to $6 million in revenue from the anticipated closing date of October 31, 2024, through December 31, 2024. During the same period, it anticipates dilution in non-GAAP operating margin, non-GAAP net income, and non-GAAP earnings per share.

Upon completion of the acquisition, the Company expects the transaction to have a dilutive impact on GAAP net income and earnings per share in the first full year following closing, and anticipates a neutral and accretive impact in the second year.

Merit, headquartered in South Jordan, Utah, expects to fund the transaction through a combination of cash on hand and borrowings under its long-term credit facility. It anticipates closing the deal in the fourth quarter of this year.

Merit Chairman and CEO Fred P. Lampropoulos stated that the transaction will strengthen the company’s electrophysiology and cardiac rhythm management businesses.

“We believe the financial profile of this acquisition is highly attractive and aligns with our objectives of achieving sustainable, consistent currency growth, enhancing profitability, and generating strong free cash flow. We look forward to discussing this acquisition and our updated outlook for 2024 in our third-quarter earnings report on October 30, 2024,” said Lampropoulos.

Fred P. Lampropoulos believes that the transaction will strengthen its position in the cardiac intervention market, and estimates that the annual potential opportunity in this market exceeds $900 million in the United States, Europe, the Middle East and Africa (EMEA), and the Asia-Pacific region. Specifically, starting from fiscal year 2025, the increase in Cook's leadership management business has enabled Merit's annualized total revenue from electrophysiology and rhythm management to exceed $100 million, serving the global cardiac intervention market.

Cook Medical is a medical device company headquartered in Indiana, USA, founded in 1963 by Mr. Bill Cook and his wife. Currently, Cook Medical operates in 135 countries and regions worldwide. Its product portfolio primarily includes vascular interventional and surgical medical products, covering multiple fields such as critical care, endoscopy, otolaryngology/head and neck surgery, reproductive health, general surgery, and urology. The company’s manufacturing facilities are mainly located in the United States, Europe, and Australia. It maintains six global logistics distribution centers and multiple local warehousing and distribution centers, employing over 10,000 people worldwide.

In the field of reproductive health, Cook Medical has been deeply engaged for over 40 years, successfully developing products for obstetrics and gynecology, in vitro fertilization (IVF), and assisted reproductive technology (ART). These include the development of the world’s first needle specifically designed for IVF treatment, used to transfer IVF embryos into the uterine cavity. Additionally, Microvol™ technology reduces the volume of media required for transfer. Furthermore, the Bakri Postpartum Balloon with Rapid Infusion Assembly is used to provide temporary control or reduction of postpartum uterine bleeding when conservative management is indicated.

Furthermore, over the past few years, Cook Medical has undergone significant changes in its customer base, supply chain, and ways of working. To ensure success in this new phase of development, its global leadership team has implemented a new five-year vision and strategic plan, developed based on extensive feedback from customers, employees, and the leadership team.

Public information indicates that, in order to execute its "Five-Year Vision and Strategic Plan," Cook Medical has undertaken several significant initiatives in recent years, including divesting business units and implementing layoffs.

Merit Medical, established in 1987, is engaged in the development, manufacturing, and distribution of proprietary single-use medical devices for interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customer hospitals worldwide, with a domestic and international sales and clinical support team totaling more than 700 people, and employs approximately 7,000 people globally.

Notably, Merit has emerged as a global leader in the fields of interventional radiology and cardiology. With over three decades of continuous development and innovation, the company has repeatedly been ranked among the “Top 100 Global Medical Device Companies.”

This June, Merit Medical also partnered with Medtronic to provide it with the Kyphon KyphoFlex, a single steerable balloon catheter used for treating minimally invasive vertebral compression fractures (VCF).

It is understood that the Kyphon KyphoFlex is a steerable, flexible catheter used to treat pathological vertebral fractures caused by osteoporosis, cancer, or benign lesions.

Under the agreement between the two parties, Medtronic will assume full responsibility for the sales, marketing, and distribution of the product, while Rematon will be responsible for manufacturing the catheter, including quality and safety control, regulatory affairs, and lifecycle management. This collaboration further deepens the existing partnership between the two companies. Previously, Rematon had supplied Medtronic with Kyphon Xpander inflation devices for use in balloon kyphoplasty.

It is reported that Balloon Kyphoplasty (BKP) is a percutaneous treatment for tumor-related vertebral compression fractures. The procedure aims to restore vertebral height using an orthopedic balloon and correct vertebral compression fractures caused by osteoporosis, cancer, or benign lesions.

This procedure involves introducing a small balloon into the vertebral body via a cannula and inflating it to elevate the collapsed vertebra. Subsequently, the balloon is deflated and removed, and the resulting cavity is controllably filled with bone cement to help form an internal scaffold, thereby stabilizing the fracture.

Merit Medical’s Kyphon KyphoFlex Cannula Enables Precise and Controlled Creation of Target Cavities in Vertebral Augmentation Procedures. The cannula’s curved design allows for more flexible trajectory adjustments within the vertebral body, facilitating optimal target positioning and complementing Medtronic’s existing bilateral balloon kyphoplasty portfolio.

——

Currently, the interventional cardiology and peripheral vascular device market is experiencing robust growth. Forecasts indicate significant expansion, with the market expected to reach an impressive $41.9003 billion by 2030. This represents a compound annual growth rate (CAGR) of 8.5% from 2021 to 2030.

These figures underscore the growing demand for and importance of interventional cardiology and peripheral vascular devices within the healthcare industry. As technological advancements and medical innovations continue to emerge, the market’s growth trajectory is expected to persist, benefiting patients worldwide.

Merit Medical is a leading manufacturer of proprietary medical devices for interventional, diagnostic, and therapeutic procedures, playing a pivotal role particularly in the fields of cardiology, radiology, oncology, critical care, and endoscopy.

Merit Medical stated that the acquisition of Cook Medical’s relevant businesses will strengthen its electrophysiology and cardiac rhythm management portfolios. What further surprises will the company bring to the industry? We will continue to monitor developments closely.